help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fayadat, L.
Right arrow Articles by Franc, J. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fayadat, L.
Right arrow Articles by Franc, J. L.
Right arrowPubmed/NCBI databases
*Substance via MeSH
Endocrinology Vol. 139, No. 10 4277-4285
Copyright © 1998 by The Endocrine Society


ARTICLES

Human Thyroperoxidase Is Largely Retained and Rapidly Degraded in the Endoplasmic Reticulum. Its N-Glycans Are Required for Folding and Intracellular Trafficking

Laurence Fayadat1, Patricia Niccoli-Sire, Jeanne Lanet and Jean Louis Franc

Institut National de la Santé et de la Recherche Médicale (Unité 38), Faculté de Médecine, Université de la Méditerranée, 13385 Marseille, Cedex 5, France

Address all correspondence and requests for reprints to: Jean-Louis Franc, INSERM U38, Faculté de Médecine, 27 Bd Jean Moulin, 13385 Marseille, Cedex 5, France. E-mail: Jean-Louis.Franc{at}medecine.univ-mrs.fr


    Abstract
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Human thyroperoxidase (hTPO), a type I transmembrane heme containing glycoprotein, catalyzes iodide organification and thyroid hormone synthesis and plays a major role in thyroid autoimmunity. Whereas hormonosynthesis occurs at the apical membrane of thyroid cells, TPO localizes mainly in the perinuclear membrane and the endoplasmic reticulum. To establish the intracellular trafficking and the structural characteristics of hTPO in the various cell compartments, hTPO was stably expressed in the Chinese hamster ovary cell line, and its folding was studied with two monoclonal antibodies (mAbs): mAb 47, recognizing a linear epitope; and mAb 15, recognizing a conformational epitope present in the mature protein. The results show that only 15–20% of hTPO molecules were able to acquire a conformation suitable for the recognition by mAb 15. On the other hand, only a part (~15%) of the latter were able to reach the plasma membrane. The hTPO, unable to fold correctly, was more rapidly degraded than that recognized by mAb 15 (half-time, 2 h vs. 7 h). Study of the carbohydrate content of hTPO showed that N-glycans with complex-type structure were found only on hTPO at the cell surface, whereas intracellular hTPO bore high-mannose-type structures. Taken together, these data demonstrate that the intracellular pool of enzyme is formed of newly synthesized molecules and is not caused by recycling of mature hTPO from the cell surface. Complete inhibition of hTPO N-glycosylation with tunicamycin led to a 95% decrease in hTPO at the plasma membrane and, thus, to a decrease in enzymatic activity at the cell surface, emphasizing the role of N-glycans in the intracellular trafficking of hTPO. However, inhibition of formation of complex-type structures with deoxymannojirimycin and of O-glycans with phenyl-{alpha}-GalNAc did not influence the intracellular trafficking and enzymatic activity of hTPO.


    Introduction
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
THYROPEROXIDASE (TPO) is a membrane-bound, glycosylated hemoprotein protein that plays a key role in thyroid hormone synthesis by catalyzing both the iodination of thyroglobulin and the coupling of some of the iodotyrosyl residues to form the thyroid hormones (1, 2). Human TPO (hTPO) is the thyroid microsomal antigen implicated in autoimmune thyroid disease (3, 4). hTPO is a 933-amino acid type I integral apical membrane protein that contains a large extracytoplasmic domain oriented toward the follicular lumen that contains thyroglobulin, the prothyroid hormone (5, 6, 7). This domain contains the catalytic site and four potential N-glycosylation sites (Asn129, Asn307, Asn342, and Asn369). The fifth Asn-X-Thr sequence found (Asn 478) is not suitable for glycosylation because the X residue is proline (8). In thyroid cells, TPO catalyzes both thyroglobulin iodination and hormonosynthesis at the apical cell surface. This enzyme is localized mainly in the endoplasmic reticulum (ER) and in the perinuclear membrane. Only a small part of peroxidase activity was detected at the apical surface (for review, see Ref. 9). Kuliawat et al. (10) and Penel et al. (11) demonstrated that no more than 30% of immunoprecipitated TPO was detected at the cell surface of porcine thyrocytes cultured on porous filters. Recent work on glycoprotein maturation clearly demonstrated that the major limiting step in the protein export from the ER is a quality control in which unfolded or misfolded proteins are retained and then degraded (12). To determine whether, in transfected cells, most of the hTPO is associated with the ER (as in thyroid), we transfected Chinese hamster ovary (CHO) cells with hTPO complementary DNA (cDNA). Because folding and intracellular trafficking of hTPO had never been studied before, we investigated the process by which newly synthesized hTPO molecules are transported from the ER to the cell surface. We focused on co- and posttranslational modifications, such as folding and N- and O-glycosylation. Effectively, the carbohydrate moieties of glycoproteins are implicated in many functions, such as maintenance of protein conformation and solubility, protection against uncontrolled proteolysis, protein transport, and mediation of biological activities (13, 14).


    Materials and Methods
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Construction of pcDNA3-hTPO
A full-length 3060-kb hTPO cDNA (kindly provided by B. Rapoport) was cloned into the HindIII and XbaI sites of the eukaryotic transfer vector pcDNA3 (InVitrogen, Leak, The Netherlands). Pure plasmid DNA preparations were obtained with the Wizard midipreps kit (Promega, Madison, WI).

CHO cell culture and transfection
CHO cell line (ECCAC number 85050302) was cultured in Ham’s F12 medium supplemented with 10% FBS (Boehringer-Mannheim, Mannheim, Germany), penicillin (100 IU/ml), streptomycin (100 µg/ml), and 10 mM sodium butyrate. Cells were transfected with lipofectamine (Gibco BRL, Cergy-Pontoise, France). Forty-eight hours after transfection, cells were cultured in a selection medium containing 400 µg/ml geneticin (Gibco BRL). Cells highly resistant to geneticin were subcloned by limited dilutions. Resitant colonies were screened for positive hTPO expression by Western blot analysis. One selected clone was expended for further study and maintained in the same selective medium.

Metabolic labeling and extraction of hTPO
After preincubation during 16 h with 10 mM sodium butyrate, cells were incubated in a methionine- and cysteine-free DMEM supplemented with 10% FBS, 10 mM sodium butyrate, and 10 µCi/ml 35S-(Met + Cys) (Expre35S35S label, NEN, Le Blanc-Menil, France). Times of incubation with radioactivity varied from 30 min to 5 h. For pulse-chase studies, cells were preincubated for 30 min in Met- and Cys-free DMEM supplemented with 10% dialyzed FBS and 10 mM sodium butyrate and were subsequently pulsed for 30 min in the same culture medium supplemented with 10 µCi/ml 35S-(Met + Cys). After the pulse, the radiolabeling medium was removed, the cell surface was washed twice with 1 ml Ham’s F12 medium, and then cells were chased for times between 30 min and 72 h in culture medium supplemented with 5 mM Met and 5 mM Cys and, when indicated, with 10 mM cycloheximide. When the chase was completed, cells were kept on ice, washed twice with 2 ml ice-cold PBS, and scraped in 600 µl extraction buffer containing Tris-HCl 50 mM (pH 7.4), NaCl 0.15 M, Triton X-100 1%, deoxycholic acid 0.3%, and protease inhibitor cocktail (Complete, Boehringer-Mannheim). The cells were then tumbled for 20 min at 4 C (vortexing every 2 min) and centrifuged for 3 min at 10,000 x g.

Immunoprecipitation and electrophoresis
The radiolabeled supernatant obtained after extraction and centrifugation was saved and incubated 2 h at room temperature with various monoclonal antibodies (mAbs) directed against hTPO. These mAbs had been previously complexed with protein A-Sepharose (Zymed Laboratories, San Francisco, CA) by incubation overnight at 4 C. Immune complexes were then retrieved by a brief centrifugation (10,000 x g, 10 sec) and washed four times with 1 ml of TPO extraction buffer and once with 1 ml PBS. The precipitated proteins were separated from antibody-protein A Sepharose complexes by boiling for 3 min in the Laemli sample buffer containing 62 mM Tris-HCl (pH6.8), 2% SDS, 5% glycerol, and 5% 2-mercaptoethanol (2-ME). The samples were then heated at 100 C for 3 min and subjected to SDS-PAGE (7.5%). The radioactivity was visualized and quantified by a phosphorimager (Fudjix BAS 1000, Japan).

Cell surface biotynilation
Confluent cells were radiolabeled for 48 h with 35S-(Met + Cys). Cell monolayers were then washed twice with ice-cold PBS (pH 8.0) supplemented with 1 mM CaCl2 and 1 mM MgCl2 (PBS-CM) before the cross-linker sulfosuccinimidyl-2-(biotinamide) ethyl-1,3'-dithiopropionate (NHS-SS-biotin, Pierce, Rockford, IL) was added at the concentration of 0.5 mg/ml in PBS-CM for 20 min on ice. Cross-linker was removed, and the same operation was repeated once. Then the medium was removed, and the remaining reactive NHS-SS-biotin was blocked by addition of 50 mM NH4Cl in PBS-CM for 10 min on ice and under gentle agitation. The cells were then washed twice with PBS-CM before being harvested. After extraction, the proteins were incubated 2 h with previously prepared mAb 47- and mAb 15-protein A Sepharose complexes. Then immunoprecipitated TPO was separated from the protein A Sepharose pellet by heating 5 min at 100 C after addition of 10 µl of 10% SDS and 500 µl hTPO extraction buffer. The suspension was diluted with 500 µl hTPO extraction buffer and then centrifuged 3 min at 10,000 x g. The supernatant was incubated 2 h with avidin-agarose (Pierce). Biotinylated surface hTPO and intracellular hTPO were separated by centrifugation (10 sec, 10,000 x g). The beads were washed four times with hTPO extraction buffer and once with PBS, resuspended in electrophoretic buffer, and boiled for 5 min. The totality of supernatant corresponding to the cell surface fraction, and only one tenth of the supernatant corresponding to the intracellular fraction, were analyzed by SDS-PAGE.

Deglycosylation of hTPO
We adopted the following methods after doing assays to optimize hTPO deglycosylation. Intracellular and cell surface hTPO were separated by biotinylation method. After denaturation and reduction with SDS and 2-ME, the samples were diluted with the buffer used for incubation with glycosidase [50 mM Tris-HCl (pH 8.5), 1% Triton X-100 for peptide-N-glycanase F (PNGase F) and 50 mM acetoacetic buffer (pH 5.0), 1% Triton X-100 for ß-endo-N-acetylglucosaminidase H (Endo H)] to obtain a final concentration of 0.1% SDS and 0.05% 2-ME. The samples were incubated for 16 h at 37 C with 1 U PNGase F or 5 mU Endo H (Boehringer Mannheim). Controls were done under the same conditions as for the corresponding assays, except that the deglycosylation enzymes were omitted. The samples were then prepared for analysis by SDS-PAGE in denaturing conditions.

O-glycosylation determination
Cells were incubated 48 h with 10 mM sodium butyrate. In one dish, 2 mM phenyl-{alpha}-GalNAc was added to the culture medium 1 h before addition of sodium butyrate. Intracellular and cell-surface TPO were separated by biotinylation technique, as described above, and were subjected to SDS-PAGE. Proteins were then electrotransferred overnight to a polyvinylidene difluoride sheet (Immobilon P. Millipore, St. Quentin Yvelines, France). The polyvinylidene difluoride blot was blocked with 5% BSA in 20 mM Tris-HCl (pH 7.4), 50 mM NaCl (TBS), rinsed twice for 10 min with TBS supplemented with 1 mM MgCl2, 1 mM CaCl2, and 1 mM MnCl2 (TBS-C). The blot was incubated 2 h at room temperature with Jacalin-biotin (Sigma, St. Louis, MO) diluted at 1/1000 in TBS-C, 1% BSA. The membrane was washed five times with TBS-C and then incubated 2 h at room temperature with avidine-horseradish peroxidase (Amersham, Les Ullis, France) diluted at 1/5000 in TBS-C, 1% BSA. The revelation was done by chemiluminescence (Pierce).

Enzymatic activity
Enzymatic activity was investigated as in Ref. 15 , with slight modifications. Forty-eight hours before assaying hTPO enzymatic activity, we supplemented the cell culture medium with 10 mM sodium butyrate. Then the medium was removed, and cells were washed twice with ice-cold PBS buffer. The incubation mixture contained BSA (5 mg/ml in PBS) and Na125I (106 cpm/ml). The reaction was initiated by addition of H2O2 to obtain a final concentration of 0.5 mM. Cells were incubated for 20 min at room temperature. At the end of this incubation time, the medium was transferred to cold reaction tubes, and the cell surface was washed once with 0.5 ml PBS. Then 1 ml ice-cold 20% (wt/vol) trichloroacetic acid, supplemented with 10-4 M KI, was added to each tube. After 20 min at 4 C, the suspension was centrifuged (2000 x g, 6 min). The supernatant was discarded, and the acid-insoluble iodinated material obtained was washed 3 times with 2 ml of 10% trichloroacetic acid (TCA). The radioactivity remaining in the pellet was counted.


    Results
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Folding and intracellular trafficking of hTPO in CHO cells
We transfected CHO cell line with human hTPO cDNA and isolated a cell clone expressing a high level of hTPO molecules. Two mAbs directed against hTPO molecules were used to follow the folding of this protein: mAb 47 (which binds to a linear epitope) and mAb 15 (which recognizes a conformational epitope) (16, 17). To monitor the folding of nascent hTPO during synthesis in CHO cells, we used pulse-chase experiments. CHO cells expressing hTPO were pulse-labeled for 30 min with 35S-(Met + Cys) and then chased for various times (0.5–48 h) in the presence of an excess of cold methionine and cysteine. The extraction medium was supplemented with 100 mM iodoacetamide to prevent further formation of additional disulfide bonds and folding of the protein. hTPO was immunoprecipitated with mAb 15, mAb 47, or by coupling the two mAbs (Fig. 1Go). The use of the couple mAb 15 + mAb 47 in the immunoprecipitation experiments allowed us to recover more than 90% of hTPO expressed in CHO cells. The same results were obtained using polyclonal antibodies directed against hTPO or using mAb 47 alone if the cell extract was obtained with 1% SDS (data not shown). After the pulse, newly synthesized hTPO molecules were strongly recognized by mAb 47 but were not recognized by mAb 15. After 0.5 h of chase, an increased amount of hTPO was immunoprecipitated with the mAb 47. This is certainly caused by a synthesis or a completion of 35S-(Met + Cys) hTPO that continues during some minutes after the addition of the chase medium. More interestingly, at this time, 18% of the hTPO recognized by mAb 15 + mAb 47 was recognized by mAb 15. At longer chase periods, there was no increase in these molecules, and they were relatively stable: we noted a decrease of only 50% between 1 and 24 h of chase. In contrast, hTPO molecules recognized only by mAb 47 were rapidly degraded. Depending on the experiments, the half-life of hTPO molecules varied from 2–4 h for the hTPO molecules recognized by mAb 47 and from 7–11 h for the hTPO molecules recognized by mAb 15. The quantity of hTPO immunoprecipitated by mAb 15 + mAb 47 was similar to or slightly higher than the sum of the hTPO immunoprecipitated by mAb 15 and by mAb 47. These results showed that mAb 47 is unable to immunoprecipitate all hTPO molecules; thus, the linear epitope for the mAb 47 is accessible only when hTPO is in an unfolded state. This was confirmed by an immunofluorescence study, in which, in contrast to mAb 15, mAb 47 was not able to recognize the hTPO at the level of the plasma membrane (data not shown).



View larger version (16K):
[in this window]
[in a new window]
 
Figure 1. 35S-(Met + Cys) pulse-chase analysis of the folding of hTPO expressed in CHO cells. Cells were preincubated for 30 min in methionine- and cysteine-free DMEM, supplemented with 10% dialyzed FBS and 10 mM sodium butyrate, and then pulsed for 30 min in the same culture medium supplemented with 10 µCi/ml 35S-(Met + Cys). After the pulse, cells were chased for various times in Ham’s F12 medium, 10% FBS supplemented with 5 mM Met and 5 mM Cys. Immunoprecipitation was done with mAb 15 (•), mAb 47 ({triangleup}), or with mAb 15 and mAb 47 ({circ}).

 
Because more than 80% of the hTPO molecules were rapidly degraded (and thus, never acquired a correct three-dimensional structure), we investigated the percentage of hTPO present at steady state (48 h) on the cell surface after radiolabeling with 35S-(Met + Cys) and cell-surface biotinylation (Fig. 2Go). Of the hTPO molecules, 85% were recovered in the intracellular compartments and only 15% at the cell surface (Fig. 2Go, lanes 2 and 4). Thus, as in thyroid cells, the majority (85–90%) of the hTPO molecules are localized in the intracellular compartments. Another interesting aspect was to determine the time needed by hTPO molecules to reach the cell surface. We thus monitored pulse-chase experiments (Fig. 3Go), using mAb 15 (because mAb 47 is unable to react with TPO present at the cell surface). The maximum of hTPO at the cell surface was found after 5 h of chase, and the majority of the hTPO molecules never reached the plasma membrane. Note that the recognition for intracellular hTPO was maximal after 5 h of chase, because we used mAb 15 and, as we previously showed (Fig. 1Go), it took at least 30 min for hTPO to acquire the three-dimensional structure suitable for the recognition by mAb 15.



View larger version (32K):
[in this window]
[in a new window]
 
Figure 2. Intracellular and cell-surface distribution of hTPO after labeling with 35S- (Met + Cys) at steady state in CHO cell line. Confluent cells were radiolabeled for 48 h with 35S-(Met + Cys). Cell monolayers were washed twice with cold PBS-C and then incubated with or without the cross-linker (NHS-SS-biotin) in PBS-C. hTPO was immunoprecipitated with the couple mAb15 + mAb 47, and then intracellular and cell surface hTPO were separated with avidin-agarose. The samples were analyzed by SDS-PAGE.

 


View larger version (26K):
[in this window]
[in a new window]
 
Figure 3. Kinetics of cell surface delivery of hTPO in CHO cells. Cells were preincubated in methionine- and cysteine-free DMEM, supplemented with 10% FBS and 10 mM sodium butyrate, and then pulse-labeled for 30 min in the same culture medium supplemented with 35S- (Met + Cys). Cells were then chased for times indicated in Ham’s F12 medium, 10% FBS supplemented with 5 mM Met and 5 mM Cys. After the chase, cells monolayers were incubated with NHS-SS-biotin, and hTPO was immunoprecipitated with mAb 15. Intracellular and cell-surface hTPO were separated with avidin agarose. Samples were analyzed by SDS-PAGE: A, SDS-PAGE analysis; B, quantification by a phosphorimager of intracellular ({circ}) and cell-surface (•) hTPO.

 
Nature of carbohydrate residues associated with hTPO
To investigate the type of N-glycans borne by hTPO expressed in CHO cells, we first separated intracellular and cell surface hTPO by using the biotinylation technique. We then investigated the nature of hTPO’s carbohydrate residues by analyzing the effects of two glycosidases (Endo H and PNGase F) on hTPO mobility on SDS-PAGE (Fig. 4Go).



View larger version (44K):
[in this window]
[in a new window]
 
Figure 4. Endo H and PNGase F digestion of hTPO. Cells were labeled for 16 h with 35S-(Met + Cys). After cell surface biotinylation, extraction, and immunoprecipitation, hTPO was diluted with the appropriate buffer [50 mM acetoacetic buffer (pH 5.0) + 1% Triton X-100 for Endo H or 50 mM Tris-HCl (pH 8.5) + 1% Triton X-100 for PNGase F] and digested 16 h at 37 C with either 1 U Endo H or 5 mU PNGase F. Controls were done under the same conditions as the corresponding assay, except that enzymes were omitted. Samples were then subjected to SDS-PAGE analysis.

 
Both intracellular and cell surface hTPO ran as a specific band of 110 kDa (lanes 1 and 4); moreover, the band corresponding to cell surface hTPO was broader. After digestion of hTPO with Endo H, we observed a major change in the mobility of the intracellular hTPO (lane 2). The molecular mass became 102 kDa, and an identical pattern was obtained with PNGase F (lane 3). When cell surface hTPO was treated with Endo H, a little shift was observed for a part of the molecules (lane 5). The deglycosylation was very efficient with PNGase F, and the hTPO was converted into 92-kDa, 94-kDa, and 98-kDa forms (lane 6). Similar results were obtained when hTPO was treated by N-ethylmaleimide, an alkylation reagent, before action of Endo H and PNGase F (data not shown). These data show that intracellular hTPO expressed in CHO cells bore only high mannose-type structures, whereas cell surface TPO contained complex-type structures.

Very little is known about the O-linked carbohydrate structure of hTPO. To determine whether hTPO expressed in CHO cells bore O-glycans, we used a Western blot with Jacalin-biotin to detect O-glycan structures (18). Experiments were done with hTPO immunopurified from cell cultures treated or not with phenyl-{alpha}-GalNAc, a specific inhibitor of O-glycosylation (19). Intracellular and cell-surface hTPO were separated. After Western blot, the Jacalin lectin clearly recognized a band at 110 kDa corresponding to cell surface hTPO (Fig. 5Go, lane 2), but the lectin did not bind to intracellular hTPO (lane 1). When the cells were treated with phenyl-{alpha}-GalNAc, the intensity of the band corresponding to cell surface hTPO was reduced by 80% (lane 4).



View larger version (29K):
[in this window]
[in a new window]
 
Figure 5. Jacalin lectin binding to hTPO present at the cell surface or in the intracellular compartments. Cells were incubated 48 h with 10 mM sodium butyrate. In one dish, 2 mM phenyl-{alpha}-GalNAc was added 1 h before addition of sodium butyrate. Intracellular (I) and cell-surface (S) hTPO were separated by the cell surface biotinylation method described in Materials and Methods. After SDS-PAGE, proteins were subjected to Western blot analysis. The first incubation was done with Jacalin-biotin (diluted at 1/1000) and the second with avidine-horseradish peroxidase (diluted at 1/5000). Revelation was done by chemiluminescence. After scanning, the quantitative analysis was done with the NIH image V1.56 software.

 
Roles of carbohydrates on hTPO intracellular trafficking and enzymatic activity
Cells were treated with tunicamycin (Tu), an antibiotic that inhibits the formation of all N-linked oligosaccharides on proteins; with deoxymannojirimycin (dMM), which leads only to high mannose type structures; and with phenyl-{alpha}-GalNAc, a specific inhibitor of O-glycosylation.

After labeling the cells, 16 h with 35S-(Met + Cys) and with or without Tu, dMM, or phenyl-{alpha}-GalNAc, we biotinylated the cell-surface proteins. In another set of experiments, cells were treated 16 h with drugs, and then hTPO cell-surface activity was measured. In the control, 1.1% of 35S-hTPO was present at the cell surface (Fig. 6AGo, lanes 1 and 3). When cells were cultured in the presence of Tu, only 0.05% of hTPO reached the cell surface (Fig. 6AGo, lanes 2 and 4; and Fig. 6BGo). In the same conditions, the cell-surface activity was decreased by 50% in the presence of Tu, relative to control (Fig. 6CGo). This decrease is similar to that obtained with cycloheximide. The decrease in cell-surface activity obtained with Tu was not caused by an effect on the protein synthesis, because, in our conditions, Tu did not inhibit the protein synthesis by more than 5%. All these results show that the N-glycans are essential for intracellular transport of hTPO to the cell surface. Given these results, we thus questioned the stability and three-dimensional structure of unglycosylated hTPO. We first did a pulse-chase experiment, in the presence or absence of Tu (Fig. 7Go). The half-time of unglycosylated hTPO was strongly reduced: 3 h vs. 11 h for glycosylated hTPO. The three-dimensional structure of unglycosylated TPO was checked using a panel of 12 mAbs directed against hTPO. One of these mAbs recognizes a linear sequence, whereas the others recognize conformational epitopes. After being labeled with 35S-(Met + Cys) for 16 h, native hTPO or unglycosylated hTPO was immunoprecipitated with each of the 12 mAbs (Fig. 8Go, A and B). As expected, hTPO recognition by mAbs differed with the conformation state of the protein (Fig. 8CGo). A strong recognition was observed for mAbs 15, 53, 59, and 64. In contrast, unglycosylated hTPO was strongly recognized by mAb 47, whereas the other mAbs exhibited only a slight reactivity. The almost-complete loss of binding of several mAbs demonstrated the crucial contribution of N-glycans to protein conformation.



View larger version (17K):
[in this window]
[in a new window]
 
Figure 6. Effect of Tu on the cell surface delivery and activity of hTPO. A, Cells were labeled 16 h with 10 µCi/ml 35S-(Met + Cys) in DMEM supplemented with 10% FBS and 10 mM sodium butyrate with or without 15 µg/ml Tu. Intracellular and cell surface TPO were then separated by the cell-surface biotinylation method. Samples were analyzed by SDS-PAGE. B, Quantification by phosphorimaging of hTPO at the cell surface. C, Effect of the inhibition of N-glycosylation on the enzymatic activity of hTPO at the cell surface. Cells were preincubated 16 h with 10 mM sodium butyrate with or without 15 µg/ml Tu or 100 µg/ml cycloheximide. The incubation mixture contained BSA (5 mg/ml in PBS) and Na125I. A negative control, in which 2 mM 2-mercapto-1-methylimidasole (MMI) was added, was also done. To initiate the reaction, H2O2 was added at a final concentration of 0.5 mM. Cells were incubated for 20 min and transferred to reaction tubes. They were then precipitated and washed with 10% cold trichloroacetic acid supplemented with 10-4 M KI. Remaining radioactivity was counted.

 


View larger version (13K):
[in this window]
[in a new window]
 
Figure 7. Degradation of 35S-(Met + Cys) native or unglycosylated hTPO. Pulse-chase analysis was done as described in Fig. 1Go. Cells were incubated 16 h with (•) or without ({circ}) 15 µg/ml Tu. hTPO was immunoprecipitated with the couple mAb 15 + mAb 47. The samples were analyzed by SDS-PAGE.

 


View larger version (37K):
[in this window]
[in a new window]
 
Figure 8. Immunoprecipitation of 35S-(Met + Cys) hTPO with a panel of hTPO mAbs. After cells were labeled for 16 h with 35S-(Met + Cys), native and unglycosylated hTPO were immunoprecipitated with each of the 12 mAbs directed against the hTPO molecule. A, Native hTPO; B, unglycosylated hTPO (obtained by treatment of the CHO cells during 16 h with 15 µg/ml Tu); C, quantitation by phosphorimaging of native and unglycosylated hTPO immunoprecipitated by a panel of hTPO mAbs. Black, Native hTPO; gray, unglycosylated hTPO.

 
Because cell-surface hTPO bore complex-type oligosaccharides, we sought to determine whether these structures play a role in the intracellular trafficking and cell surface activity of the enzyme. We thus treated cells during 16 h with dMM. The cell surface and the intracellular hTPO N-glycan structures obtained in the presence of this drug were analyzed with Endo H and PNGase F. Contrary to control, cell-surface hTPO, obtained after treatment with dMM, was sensitive to Endo H (Fig. 9AGo, lanes 8 and 11). Thus dMM led to formation of hTPO, bearing only high-mannose type structures. Quantification of the bands showed that dMM did not affect the intracellular trafficking of TPO (Fig. 9BGo). This drug did not affect hTPO cell surface activity (Fig. 9CGo).



View larger version (32K):
[in this window]
[in a new window]
 
Figure 9. Effect of dMM on cell-surface delivery and activity of hTPO. A, Control of dMM action and cell surface delivery of hTPO. Cells were radiolabeled 16 h with 35S-(Met + Cys) in DMEM without cysteine and methionine, supplemented with 10% FBS and 10 mM sodium butyrate in the absence or presence of dMM (500 µg/ml). After immunoprecipitation with the couple mAb 15 + mAb 47, hTPO was digested with Endo H or with PNGase F. Samples were then analyzed by SDS-PAGE. B, Quantitative analysis by phosphorimaging of the hTPO present at the cell surface with or without dMM. C, Effect of dMM on the cell surface hTPO enzymatic activity. hTPO enzymatic activity was assayed as described in Materials and Methods.

 
To study the role of O-glycosylation, we treated the cells during 16 h with phenyl-{alpha}-GalNAc. This led, as described above, to a decrease of 80% in O-glycosylation. This treatment only slightly altered hTPO traffic and activity (data not shown).


    Discussion
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
In thyroid cells, TPO catalyzes iodide organification predominantly at the apical cell membrane, whereas the major part of this enzyme is localized in the ER and in the perinuclear membrane (9, 10, 11). To better understand the intracellular trafficking of hTPO, we stably transfected CHO cells with hTPO cDNA. In a first set of experiments, we investigated the folding of the nascent polypeptide hTPO chain. We used two mAbs: mAb 47, which links to a linear epitope; and mAb 15, which recognizes a conformational epitope present on the mature hTPO molecule (16, 17). The results (summarized in Fig. 10Go) show that only a small part (~18%) of hTPO acquired the three-dimensional structure suitable for the recognition by mAb 15, whereas the other part was rapidly degraded. This degradation process most likely occurs in the ER, the site where nascent proteins acquire their final tertiary and quaternary structure (20). Through a pulse chase experiment, we determined that only 10–15% of the molecules recognized by mAb 15 were recovered at the cell surface. Therefore, only 1.5–2% of total synthesized hTPO reaches the cell surface. This suggests that mAb 15 recognizes both an incompletely folded intermediate that cannot reach out of the ER and the completely folded protein that is able to reach the plasma membrane. Note that the incompletely folded intermediate has a longer half life than the unfolded protein recognized only by mAb 47. At steady state, the rate of TPO expressed at the cell surface was about the same in thyroid and in CHO cells. This strongly suggests that intracellular traffic of hTPO does not greatly differ between the two cell types, but we cannot totally exclude that, in thyroid cells, a somewhat-greater part of hTPO could arrive at the cell surface. Additional studies are needed to define features important for hTPO maturation. In particular, it would be necessary to establish: 1) the hypothetical role of heme in the folding of the hTPO [it has been suggested that heme is required to achieve the proper conformation of myeloperoxidase (21)]; and 2) the mechanisms of hTPO retention and degradation in the ER. The major limiting step in the protein export from the ER is a quality control in which unfolded or misfolded proteins are retained and then degraded (12). The lumen of the ER contains numerous molecular chaperones (BiP, GRP 94, hsp 90, calnexin... ); those molecules play a central role in the folding and the quality control process that limits the exportation from the ER of misfolded, unfolded, or unassembled molecules (22). hTPO interaction with molecular chaperones and potential roles of this association in the retention-degradation process remain to be elucidated. Such retention phenomena have been described for many proteins. In thyroid, a mutant Tg has been reported to be abnormally folded, retained, and degraded within the ER (23). That leads to a congenital goiter, with hypothyroidism. On the other hand, by means of an interaction with the molecular chaperone BiP, partially folded Ig light chains are retained and then degraded within the ER (24).



View larger version (10K):
[in this window]
[in a new window]
 
Figure 10. Model for the folding, degradation, and transport of hTPO. A, Unfolded form; B, partially folded form(s); C, totally folded form.

 
Protein targeting to the cell surface depends on signals contained in the primary, secondary, and tertiary structures of proteins. In this study, we focused on the role of N- and O-glycosylation on folding, transport, and activity of hTPO. The nature of N-glycans borne by TPO is debated. Foti et al. (25) and Giraud et al. (26) suggested that hTPO bore only high-mannose type structures. The group of Reesmith (27) claimed that hTPO contained both complex and high-mannose type structures. In our study, we first separated intracellular and cell surface hTPO and then deglycosylated it with Endo H and PNGase F. In CHO cells, only hTPO (present at the cell surface) bore N-glycans with complex type structures, whereas intracellular hTPO bore only high mannose-type structures. Because intracellular TPO bears only high mannose-type structures, we suggest that the intracellular TPO was localized in the ER and that the intracellular pool of enzyme does not result from a recycling mechanism or a retrograde transport from the Golgi apparatus back to the ER. The differences in the N-glycan structures (25, 26, 27) can be explained by the fact that, in both thyroid and CHO cells, hTPO was located mainly in the ER or in the perinuclear membrane. At that step, the glycoproteins have not yet been submitted to the N-glycosylation processing; and thus, they bear only high mannose type structures.

The inhibition of N-glycosylation by treatment with Tu led to a 50% diminution of enzymatic activity of TPO at the cell surface. When cells were treated with dMM (which leads only to high mannose-type structures), the activity was not (or only slightly) decreased. N-glycans thus play a major role, but complex type N-glycan formation is not essential to the expression of hTPO activity at the cell surface. The work presented here extends that of Giraud et al. (26), who reported that the enzymatic activity of hTPO was inhibited by Endo H deglycosylation through alteration of the active site domain of the enzyme. In our study, because a direct interference between N-glycans and the active site of the enzyme remains uncertain, we examined more closely whether the diminution of the enzymatic activity, when cells were treated with Tu, was caused by a direct role of N-glycans on the catalytic site or by a decrease in the expression of the hTPO molecules at the cell surface. After a 16-h incubation with Tu, the cell-surface expression of newly synthesized hTPO was decreased by 95%.

Our data indicate that unglycosylated TPO has a reduced half-time (3 h vs. 11 h for glycosylated hTPO). Because a reduced half-life can be related to a misfolding of the protein, we thus determined the role of N-glycans on the three-dimensional structure of the protein. We have recently shown that an alternatively spliced form of hTPO (TPO2) has an improper folding, causing an inhibition of intracellular trafficking and a rapid degradation (28). Among the 12 mAbs directed against hTPO that we tested, only mAb 47, directed against a linear epitope (17), strongly recognizes unglycosylated hTPO. The other mAbs exhibit little (if any) reactivity toward this molecule. Thus, unglycosylated hTPO exhibits conformational changes.

Kiso et al. reported that hTPO bore O-glycans (27), whereas Foti et al. (25) reported that hTPO expressed in CHO cells did not contain O-glycans. In our system, we determined, after separation of intracellular and cell-surface TPO that (as expected) only hTPO (present at the cell surface) bears O-glycans, because O-glycosylation processing occurs in the Golgi apparatus. Furthermore it seems that O-glycans have no effect on the activity and the expression of hTPO at the cell surface. However, we cannot exclude a possible role of O-glycans in the protection of hTPO against proteolysis.

Overall, our results demonstrate that only a little part of the synthesized hTPO is able to fold correctly and to reach the cell surface. In contrast to O-glycans, N-glycans play an essential role for the correct folding, the intracellular trafficking, and the activity of hTPO.


    Acknowledgments
 
We thank B. Rapoport for kindly providing the full-lengh human TPO cDNA, J. Ruf for providing TPO mAbs, and A. Giraud and P. Carayon for reading the manuscript and for helpful discussions.


    Footnotes
 
1 During this work, L.F. was supported by ADEREM. Back

Received February 12, 1998.


    References
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Nunez J, Pommier J 1982 Formation of thyroid hormones. Vitam Horm 39:175–198[Medline]
  2. Rawitch AB, Taurog A, Chernoff SB, Dorris ML 1979 Hog thyroid peroxidase: physical, chemical, and catalytic properties of the highly purified enzyme. Arch Biochem Biophys 194:244–257[CrossRef][Medline]
  3. Czarnocka B, Ruf J, Ferrand M, Carayon P, Lissitzky S 1985 Purification of the human peroxidase and its identification as the microsomal antigen involved in autoimmune diseases. FEBS Lett 190:147–152[CrossRef][Medline]
  4. Seto P, Hirayu H, Magnusson RP, Gestautas J, Portmann L, Degroot LJ, Rapoport B 1987 Formation of thyroid hormones. J Clin Invest 80:1205–1208
  5. Kimura S, Kotani T, Wesley-McBride O, Umeki K, Hirai K, Narayama T, Ohtaki S 1987 Human thyroid peroxidase: complete cDNA and protein sequence, chromosome mapping, and identification of two alternatively spliced mRNAs. Proc Natl Acad Sci USA 84:5555–5559[Abstract/Free Full Text]
  6. Magnusson RP, Chazenbalk GD, Gestautas J, Seto P, Filetti S, Degroot L, Rapoport B 1987 Molecular cloning of the complementary deoxyribonucleic acid for human thyroid peroxidase. Mol Endocrinol 1:856–861[CrossRef][Medline]
  7. Libert F, Ruel J, Ludgate M, Swillens S, Alexander N, Vassart G, Dinsart C 1987 Thyroperoxidase, an auto-antigen with mosaic structure made of nuclear and mitochondrial gene modules. EMBO J 6:4193–4196[Medline]
  8. Roitsch T, Lehle L 1989 Stuctural requirement for protein N-glycosylation. Eur J Biochem 181:525–529[Medline]
  9. Eckholm R 1981 Iodination of thyroglobulin. An intracellular or extracellular process? Mol Cell Endocrinol 24:141–163[CrossRef][Medline]
  10. Kuliawat R, Lisanti M, Arvan P 1995 Polarized distribution and delivery of plasma membrane proteins in thyroid follicular epithelial cells. J Biol Chem 270:2478–2482[Abstract/Free Full Text]
  11. Penel C, Gruffat D, Alquier C, Benoliel AM, Chabaud O 1997 Thyrotropin regulates the pool of thyroperoxidase and its intracellular distribution: a quantitative confocal microscopic study. J Cell Physiol 174:160–169
  12. Hammond C, Helenius H 1995 Quality control in the secretory pathway. Curr Opin Cell Biol 7:523–529[CrossRef][Medline]
  13. West CM 1986 Current idea on the significance of protein glycosylation. Mol Cell Biochem 72:3–20[Medline]
  14. Wang C, Eufemi M, Turano C, Giartosio A 1996 Influence of the carbohydrate moiety on the stability of glycoproteins. Biochemistry 35:7305–7307
  15. Neary JT, Soodak M, Maloof F 1984 Iodination by thyroid peroxidase. Methods Enzymol 107:445–475[Medline]
  16. Ruf J, Toubert ME, Czarnocka B, Durand-Gorde JM, Ferrand M, Carayon P 1989 Relationship between immunological structure and biochemical properties of human thyroid peroxidase. Endocrinology 125:1211–1218[Abstract]
  17. Finke R, Seto P, Ruf J, Carayon P, Rapoport B 1991 Determination at the molecular cell level of a B-cell epitope on thyroid peroxidase likely to be associated with autoimmune thyroid disease. J Clin Endocrinol Metab 73:919–921[Abstract]
  18. Hortin GL, Trimpe BL 1990 Lectin affinity chromatography of proteins bearing O-linked oligosaccharides: application of jacalin-agarose. Anal Biochem 188:271–277[CrossRef][Medline]
  19. Kuan SF, Byrd JC, Basbaum C, Kim YS 1989 Inhibition of mucin glycosylation by aryl-N-acetyl-{alpha}-galactosaminides in human colon cancer cells. J Biol Cell 264:19271–19277
  20. Kopito RR 1997 ER quality control: the cytoplasmic connection. Cell 88:427–430[CrossRef][Medline]
  21. Nauseef N, Mc Cormick S, Clark RA 1995 Calreticulin functions as a molecular chaperone in the biosynthesis of myeloperoxidase. J Biol Chem 270:4741–4747[Abstract/Free Full Text]
  22. Hendrick JP, Hartl FU 1993 Molecular chaperones functions of the heat-shock proteins. Annu Rev Biochem 62:349–384[CrossRef][Medline]
  23. Kim PS, Kwon O-Y, Arvan P 1996 An endoplasmic reticulum starage disease causing congenital goiter with hypothyroidism. J Cell Biol 133:517–527[Abstract/Free Full Text]
  24. Knittler MR, Dirks S, Haas IG 1995 Molecular chaperones involved in protein degradation in the endoplasmic reticulum: quantitative interaction of the heat shock cognate protein Bip with partially folded immunoglobulin light chains that are degraded in the endoplasmic reticulum. Immunology 92:1767–1768
  25. Foti D, Rapoport B 1990 Carbohydrate moieties in recombinant human thyroid peroxidase: role in recognition by antithyroid peroxidase antibodies in Hashimoto thyroiditis. Endocrinology 126:2983–2988[Abstract]
  26. (Giraud A, Franc JL, Long Y, Ruf J 1992 Effect of deglycosylation of human thyroperoxidase on its enzymatic activity and immunorectivity. J Endocrinol 132:317–323[Abstract/Free Full Text]
  27. Kiso Y, Furmaniak J, Morteo C, Rees-Smith B 1992 Analysis of carbohydrate residues on human thyroid peroxidase (TPO) and thyroglobulin (Tg) and effects of deglycosylation, reduction and unfolding on autoantibodies binding. Autoimmunity 12:259–269[Medline]
  28. Niccoli P, Fayadat L, Panneels V, Lanet J, Franc JL 1997 Human thyroperoxidase in its alternatively spliced form (TPO2) is enzymatically inactive and exhibits change in intracellular processing and trafficking. J Biol Chem 47:29487–29492



This article has been cited by other articles:


Home page
EndocrinologyHome page
A. Giraud, P.-J. Lejeune, J. Barbaria, and B. Mallet
A Plasminogen-Like Protease in Thyroid Rough Microsomes Degrades Thyroperoxidase and Thyroglobulin
Endocrinology, June 1, 2007; 148(6): 2886 - 2893.
[Abstract] [Full Text] [PDF]


Home page
Endocr Relat CancerHome page
J Di Cristofaro, M Silvy, A Lanteaume, M Marcy, P Carayon, and C De Micco
Expression of tpo mRNA in thyroid tumors: quantitiative PCR analysis and correlation with alterations of ret, Braf , ras and pax8 genes.
Endocr. Relat. Cancer, June 1, 2006; 13(2): 485 - 495.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
R. Ameziane-El-Hassani, S. Morand, J.-L. Boucher, Y.-M. Frapart, D. Apostolou, D. Agnandji, S. Gnidehou, R. Ohayon, M.-S. Noel-Hudson, J. Francon, et al.
Dual Oxidase-2 Has an Intrinsic Ca2+-dependent H2O2-generating Activity
J. Biol. Chem., August 26, 2005; 280(34): 30046 - 30054.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
R. Kuliawat, J. Ramos-Castaneda, Y. Liu, and P. Arvan
Intracellular Trafficking of Thyroid Peroxidase to the Cell Surface
J. Biol. Chem., July 29, 2005; 280(30): 27713 - 27718.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
E. M. Pietila, J. T. Tuusa, P. M. Apaja, J. T. Aatsinki, A. E. Hakalahti, H. J. Rajaniemi, and U. E. Petaja-Repo
Inefficient Maturation of the Rat Luteinizing Hormone Receptor: A PUTATIVE WAY TO REGULATE RECEPTOR NUMBERS AT THE CELL SURFACE
J. Biol. Chem., July 15, 2005; 280(28): 26622 - 26629.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
V. Le Fourn, M. Ferrand, and J.-L. Franc
Endoproteolytic Cleavage of Human Thyroperoxidase: ROLE OF THE PROPEPTIDE IN THE PROTEIN FOLDING PROCESS
J. Biol. Chem., February 11, 2005; 280(6): 4568 - 4577.
[Abstract] [Full Text] [PDF]


Home page
Eur J EndocrinolHome page
C. Rodrigues, P. Jorge, J. P. Soares, I. Santos, R. Salomao, M. Madeira, R. V. Osorio, and R. Santos
Mutation screening of the thyroid peroxidase gene in a cohort of 55 Portuguese patients with congenital hypothyroidism
Eur. J. Endocrinol., February 1, 2005; 152(2): 193 - 198.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
S. Morand, D. Agnandji, M.-S. Noel-Hudson, V. Nicolas, S. Buisson, L. Macon-Lemaitre, S. Gnidehou, J. Kaniewski, R. Ohayon, A. Virion, et al.
Targeting of the Dual Oxidase 2 N-terminal Region to the Plasma Membrane
J. Biol. Chem., July 16, 2004; 279(29): 30244 - 30251.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
M. Ferrand, V. Le Fourn, and J.-L. Franc
Increasing Diversity of Human Thyroperoxidase Generated by Alternative Splicing. CHARACTERIZATION BY MOLECULAR CLONING OF NEW TRANSCRIPTS WITH SINGLE- AND MULTISPLICED mRNAs
J. Biol. Chem., January 31, 2003; 278(6): 3793 - 3800.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
A.-C. Gerard, M.-C. Many, C. Daumerie, S. Costagliola, F. Miot, J. J. M. DeVijlder, I. M. Colin, and J.-F. Denef
Structural Changes in the Angiofollicular Units between Active and Hypofunctioning Follicles Align with Differences in the Epithelial Expression of Newly Discovered Proteins Involved in Iodine Transport and Organification
J. Clin. Endocrinol. Metab., March 1, 2002; 87(3): 1291 - 1299.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
N. Samih, S. Hovsepian, A. Aouani, D. Lombardo, and G. Fayet
Glut-1 Translocation in FRTL-5 Thyroid Cells: Role of Phosphatidylinositol 3-Kinase and N-Glycosylation
Endocrinology, November 1, 2000; 141(11): 4146 - 4155.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Cell Physiol.Home page
A. L. Stevens, S. Breton, C. E. Gustafson, R. Bouley, R. D. Nelson, D. E. Kohan, and D. Brown
Aquaporin 2 is a vasopressin-independent, constitutive apical membrane protein in rat vas deferens
Am J Physiol Cell Physiol, April 1, 2000; 278(4): C791 - C802.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
L. Fayadat, S. Siffroi-Fernandez, J. Lanet, and J.-L. Franc
Calnexin and Calreticulin Binding to Human Thyroperoxidase Is Required for Its First Folding Step(s) But Is Not Sufficient to Promote Efficient Cell Surface Expression
Endocrinology, March 1, 2000; 141(3): 959 - 966.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
L. Fayadat, P. Niccoli-Sire, J. Lanet, and J.-L. Franc
Role of Heme in Intracellular Trafficking of Thyroperoxidase and Involvement of H2O2 Generated at the Apical Surface of Thyroid Cells in Autocatalytic Covalent Heme Binding
J. Biol. Chem., April 9, 1999; 274(15): 10533 - 10538.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
X. Zhang and P. Arvan
Cell Type-dependent Differences in Thyroid Peroxidase Cell Surface Expression
J. Biol. Chem., October 6, 2000; 275(41): 31946 - 31953.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
L. Fayadat, S. Siffroi-Fernandez, J. Lanet, and J.-L. Franc
Degradation of Human Thyroperoxidase in the Endoplasmic Reticulum Involves Two Different Pathways Depending on the Folding State of the Protein
J. Biol. Chem., May 19, 2000; 275(21): 15948 - 15954.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles